An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough

Rayid Abdulqawi; Imran Satia; Kimberley J Holt; Rachel Dockry; Shilpi Sen; Jaclyn A Smith

doi:10.1183/23120541.00447-2021

An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough

ERJ Open Res. 2021 Sep 20;7(3):00447-2021. doi: 10.1183/23120541.00447-2021. eCollection 2021 Jul.

Authors

Rayid Abdulqawi^{1

2

3

4}, Imran Satia^{1

5

6

4}, Kimberley J Holt^{1

3}, Rachel Dockry^{1

3}, Shilpi Sen³, Jaclyn A Smith^{1

3}

Affiliations

¹ University of Manchester, Division of Infection, Immunity and Respiratory Medicine, and Manchester Academic Health Science Centre, Manchester, UK.
² King Fahad Specialist Hospital-Dammam, and Dept of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
³ Manchester University NHS Foundation Trust, Manchester, UK.
⁴ These authors contributed equally.
⁵ McMaster University, Dept of Medicine, Division of Respirology, Hamilton, Canada.
⁶ Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, Canada.

Abstract

Blocking NMDA receptors with memantine in refractory chronic cough patients is poorly tolerated and demonstrates no improvement in cough https://bit.ly/3kgx2g1.

Grants and funding

207504/B/17/Z/WT_/Wellcome Trust/United Kingdom